Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18


Jun. 20 2018, Updated 8:05 a.m. ET

Stock performance

On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63. The close on June 18 was ~89% higher than its 52-week low of $0.33 on April 24. In the week ended June 15, Actinium Pharmaceuticals stock closed at $0.50, which reflected ~15% growth from the prior week’s close of $0.44 on June 8.

Article continues below advertisement

Reason for the stock price hike

On June 13, Actinium Pharmaceuticals announced the treatment of its first patient in the phase one trial that is evaluating Actimab-A and CLAG-M (cladribine, cytarabine, and filgrastim with mitoxantrone) combination therapy for the treatment of patients with relapsed/refractory (or R/R) acute myeloid leukemia (or AML).

Actinium Pharmaceuticals’ phase 1 trial will carry out a single administration of Actimab after treatment with CLAG-M and evaluate the safety, tolerability, response rates, progression-free survival, overall survival, and rates of BMT (bone marrow transplant). Actinium Pharmaceuticals’ Actimab-A is an anti-CD33 monoclonal antibody lintuzumab, which is labeled with radioisotope actinium-225.

Presently, phase one trials are ongoing at the Medical College of Wisconsin with Actimab-A and CLAG-M combination regimen. The success in the clinical trials will help Actinium Pharmaceuticals commercialize the drug in different markets.

Analyst recommendations

Of the six analysts tracking Actinium Pharmaceuticals in June 2018, one of them recommended a “strong buy,” while five recommended a “buy.” On June 18, Actinium Pharmaceuticals had a consensus 12-month target price of $4.25, which represents a ~630.1% return on investment over the next 12 months.

Peer ratings

Of the ten analysts tracking Neurocrine Biosciences (NBIX) in June 2018, all of them recommended a “buy.” Of the 21 analysts tracking BlueBird Bio (BLUE), ~67% of analysts recommended a “buy.” Of the ten analysts tracking Loxo Oncology (LOXO) in June 2018, ~90% of the analysts recommended a “buy.”

On June 18, Neurocrine Biosciences, BlueBird Bio (BLUE), and Loxo Oncology had a consensus 12-month target price of $108.8, $219.72, and $203, respectively, which represents a ~5.3%, ~25.1%, and ~13.4% return on investment over the next 12 months, respectively.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.